As of the latest Form 4 filed Jul 2, 2026.
What Beam Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 29 most recent filings for BEAM.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-06-30 | Simon Amy Chief Medical Officer | SSale | −373.00 | $34.73 | $13.0K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Evans John M. CEO | SSale | −1.90K | $34.84 | $66.2K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Evans John M., CEO | SSale | −23.1K | $34.26 | $791K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Evans John M., CEO | MExercise | +25.0K | $1.03 | $25.8K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Evans John M., CEO | SSale | −11.6K | $35.91 | $416K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Evans John M., CEO | SSale | −13.4K | $35.13 | $472K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Evans John M., CEO | MExercise | +6.34K | $1.03 | $6.53K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Evans John M., CEO | MExercise | +18.7K | $0.67 | $12.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-26 | FMR LLC 10% owner | SSale | −251K | $35.26 | $8.87M | No | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | FMR LLC, 10% owner | SSale | −33.4K | $35.12 | $1.17M | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Ciaramella Giuseppe President | MExercise | +29.0K | $1.03 | $29.9K | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Ciaramella Giuseppe, President | MExercise | +6.50K | $0.67 | $4.36K | No | Form 4 ↗ |
| 2026-04-06 | 2026-04-01 | Evans John M. CEO | SSale | −30.1K | $24.58 | $739K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-01 | Simon Amy Chief Medical Officer | SSale | −6.70K | $24.58 | $165K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-01 | Cavanagh Bethany J SVP, Finance and Treasurer | SSale | −3.24K | $24.58 | $79.7K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-01 | Bellon Christine Chief Legal Officer | SSale | −5.96K | $24.58 | $146K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-01 | Ciaramella Giuseppe President | SSale | −11.8K | $24.58 | $290K | Yes (planned) | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Bellon Christine Chief Legal Officer | AAward | +20.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Cavanagh Bethany J SVP, Finance and Treasurer | AAward | +20.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Simon Amy Chief Medical Officer | AAward | +31.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Emany Sravan Kumar Chief Financial Officer | AAward | +31.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Ciaramella Giuseppe President | AAward | +40.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Evans John M. CEO | AAward | +90.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Evans John M., CEO | SSale | −25.0K | $22.76 | $569K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Evans John M., CEO | MExercise | +25.0K | $0.67 | $16.8K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Evans John M., CEO | SSale | −25.0K | $22.37 | $559K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-03-30 | Evans John M., CEO | MExercise | +25.0K | $0.67 | $16.8K | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Ciaramella Giuseppe President | SSale | −35.0K | $32.00 | $1.12M | Yes (planned) | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Ciaramella Giuseppe, President | MExercise | +35.0K | $17.00 | $595K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BEAM’s full analysis or the market-wide insider trading feed. The tabs above jump to BEAM’s other SEC data.
Source: SEC Form 4 filings for BEAM, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.